HomeNewsWorldSanofi, GSK Covid-19 vaccine found effective against Omicron

Sanofi, GSK Covid-19 vaccine found effective against Omicron

In a trial involving 13,000 adults, when given as a first dose the vaccine demonstrated an efficacy rate of 64.7% in people with symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

June 24, 2022 / 13:23 IST
Representative image.

Representative image.

Late-stage data on an experimental Covid-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the vaccine, the French drugmaker said on June 24.

The vaccine targets the beta variant – first identified in South Africa – as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, when given as a first dose the vaccine demonstrated an efficacy rate of 64.7% in people with symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

"Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.

Sanofi’s Paris-listed shares were up about 1.4% in morning trading.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The new data supporting the vaccine will be submitted to regulatory authorities with the hope of making the shot available later this year, the companies said on Friday.

Reuters
first published: Jun 24, 2022 01:23 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347